JP2024546996A5 - - Google Patents

Info

Publication number
JP2024546996A5
JP2024546996A5 JP2024536163A JP2024536163A JP2024546996A5 JP 2024546996 A5 JP2024546996 A5 JP 2024546996A5 JP 2024536163 A JP2024536163 A JP 2024536163A JP 2024536163 A JP2024536163 A JP 2024536163A JP 2024546996 A5 JP2024546996 A5 JP 2024546996A5
Authority
JP
Japan
Prior art keywords
sequence number
isoform
vlcdr1
vlcdr2
vlcdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024536163A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546996A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/086452 external-priority patent/WO2023111311A1/en
Publication of JP2024546996A publication Critical patent/JP2024546996A/ja
Publication of JP2024546996A5 publication Critical patent/JP2024546996A5/ja
Pending legal-status Critical Current

Links

JP2024536163A 2021-12-16 2022-12-16 細胞療法に使用するためのcd117の識別可能な細胞表面タンパク質変異体 Pending JP2024546996A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP21215028.8 2021-12-16
EP21215028 2021-12-16
EP22164796.9 2022-03-28
EP22164796 2022-03-28
EP22207926 2022-11-16
EP22207926.1 2022-11-16
PCT/EP2022/086452 WO2023111311A1 (en) 2021-12-16 2022-12-16 Discernible cell surface protein variants of cd117 for use in cell therapy

Publications (2)

Publication Number Publication Date
JP2024546996A JP2024546996A (ja) 2024-12-26
JP2024546996A5 true JP2024546996A5 (cg-RX-API-DMAC7.html) 2025-12-23

Family

ID=84981434

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024536163A Pending JP2024546996A (ja) 2021-12-16 2022-12-16 細胞療法に使用するためのcd117の識別可能な細胞表面タンパク質変異体

Country Status (10)

Country Link
US (1) US20250057951A1 (cg-RX-API-DMAC7.html)
EP (1) EP4448573A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024546996A (cg-RX-API-DMAC7.html)
KR (1) KR20240115920A (cg-RX-API-DMAC7.html)
AU (1) AU2022409748A1 (cg-RX-API-DMAC7.html)
CA (1) CA3240527A1 (cg-RX-API-DMAC7.html)
IL (1) IL313568A (cg-RX-API-DMAC7.html)
MX (1) MX2024007317A (cg-RX-API-DMAC7.html)
WO (1) WO2023111311A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202405110B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4540287A1 (en) * 2022-06-20 2025-04-23 CRISPR Therapeutics AG Chimeric antigen receptor specific to cd117
EP4543469A4 (en) * 2022-06-27 2026-06-03 Beam Therapeutics Inc COMPOSITIONS AND CONDITIONING METHODS OF NON-GENOTOXIC CELLS
EP4551601A1 (en) * 2022-07-07 2025-05-14 Cimeio Therapeutics AG Antibodies targeting cd117
WO2025231071A1 (en) * 2024-05-01 2025-11-06 Beam Therapeutics Inc. Compositions and methods for cell conditioning

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0578774T3 (da) 1991-04-05 1999-04-26 Univ Washington Monoklonale antistoffer mod stamcellefaktor-receptorer
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之c-kit抗體
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
EP3448995A1 (en) 2016-04-25 2019-03-06 Universität Basel Allele editing and applications thereof
US20190365806A1 (en) 2016-11-02 2019-12-05 Universität Basel Immunologically discernible cell surface variants for use in cell therapy
KR102709603B1 (ko) 2017-02-28 2024-09-27 보르 바이오파마 인크. 계통 특이적 단백질의 억제를 위한 조성물 및 방법
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
US10882915B2 (en) * 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
EP3700568A4 (en) 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
CN113164570B (zh) * 2018-08-08 2024-05-14 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
UA128431C2 (uk) 2018-11-26 2024-07-10 Форті Севен, Інк. ГУМАНІЗОВАНЕ АНТИТІЛО ДО c-Kit
JP2022529727A (ja) * 2019-04-24 2022-06-23 マジェンタ セラピューティクス インコーポレイテッド Anti-cd117 とその使用
AU2020336969B2 (en) 2019-08-29 2024-12-05 Beam Therapeutics Inc. Compositions and methods for non-toxic conditioning

Similar Documents

Publication Publication Date Title
JP6993699B2 (ja) ヒトインターロイキン-2に対する免疫刺激性ヒト化モノクローナル抗体及びその融合タンパク質
EP2788379B1 (en) Pdgf receptor beta binding polypeptides
CN114341189A (zh) 全新il-15前药及其应用
ES2774422T3 (es) Anticuerpos para IL-21
WO2021062406A1 (en) Cytokine prodrugs and dual-prodrugs
WO2019080872A1 (zh) 阻断pd-1/pd-l1信号传导途径且活化t细胞的融合蛋白及其用途
EP4192872B1 (en) Proteins binding nkg2d, cd16 and egfr
CN116323671A (zh) 具有增加的选择性的多靶向性双特异性抗原结合分子
JP2017535257A (ja) 免疫応答およびがん治療の増強に使用するための組成物および方法
JP7855521B2 (ja) ヒト抗cd33抗体及びその使用
WO2020168555A1 (zh) Cd3抗原结合片段及其应用
TW202110894A (zh) 抗alk2抗體
TW202607029A (zh) 三特異性結合蛋白、方法及其用途
JP2021508247A (ja) 抗フリズルド抗体及び使用方法
TW201520226A (zh) 泛-elr+cxc趨化因子抗體
CN116323667A (zh) 结合PSMA和γ-δT细胞受体的抗体
WO2022223001A1 (zh) 双特异性多功能融合多肽
WO2023020537A1 (zh) 一种双特异性抗体及其用途
TW202440636A (zh) Cd19/cd38多特異性抗體
TW202102544A (zh) 雙特異性抗體
JP2025500288A5 (cg-RX-API-DMAC7.html)
KR20180021875A (ko) 다중특이적 결합 단백질
US20250313644A1 (en) Antibodies capable of specifically binding tl1a and use thereof
JP7849919B2 (ja) ヒトdr3に特異的に結合する抗体及びその用途
JP2019505516A (ja) インターロイキン−17(il−17)アンタゴニストを使用してざ瘡を治療する方法